PDF下载 ( 2623 KB)
New development of small molecule compounds for hepatitis C therapy
-
摘要:
目前慢性丙型肝炎（CHC）的标准疗法为聚乙二醇干扰素-α（PEG-IFN-α）联合利巴韦林,但该疗法存在一定的局限性。近年来针对HCV生活周期的小分子抗病毒药物迅速发展,给将来的治疗带来了新的希望。
Abstract:The currently standardized therapy for hepatitis C virus(HCV) infection is the combination of a pegylated interferon alfa(PEG-IFN-α) and ribavirin,howerver,the IFN-based therapy regimen is by far still the ideal choice.Recently,some small molecules antiviral compound that specifically targets the life circle of HCV made some quick developement,and may offer hope for future therapies.
-
Key words:
- hepatitis C /
- antiviral agents /
- specifically targeted therapy for HCV
-
[1]Seeff LB.Natural history of hepatitis C[J].Hepatology,1997,26(3 Suppl 1):S21-28. [2]Shepard CW,Finelli L,Alter MJ.Global epidemiology of hepatitis C virus infection[J].Lancet Infect Dis,2005,5(9):558-567. [3]Lauer GM,Walker BD.Hepatitis C virus infection[J].N Engl J Med,2001,345(1):41-52. [4]Perz JF,Armstrong GL,Farrington LA,et al.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J].J Hepatol,2006,45(4):529-538. [5]Hoofnagle JH,Mullen KD,Jones DB,et al.Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon.A preliminary report[J].N Engl J Med,1986,315(25):1575-1578. [6]Global surveillance and control of hepatitis C.Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board,Antwerp,Belgium[J].JViral Hepat,1999.6(1):35-47. [7]Lindenbach BD,Rice CM.Unravelling hepatitis C virus replication from genome to function[J].Nature,2005,436(7053):933-938. [8]Kwong AD,McNair L,Jacobson I,et al.Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors[J].Curr Opin Pharmacol,2008,8(5):522-531. [9]Reesink HW,Zeuzem S,Weegink CJ,et al.Rapid decline of viral RNA in hepatitis C patients treated with VX-950:a phase Ib,placebo-controlled,randomized study[J].Gastroenterology,2006,131(4):997-1002. [10]Zeuzem S.Telaprevir,peginterferon alfa-2a,and ribavirin for 28 days in chronic hepatitis C patients[J].J Hepatol,2008,49(2):157-159. [11]de Bruijne J,Weegink CJ,Jansen PL,et al.New developments in the antiviral treatment of hepatitis C[J].Vox Sang,2009,97(1):1-12. [12]Kwo P.HCV SPRINT-1:boceprevir plus peginterferon-alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients[R].The 59th Annual Meeting of the American Association for the Study of Liver Diseases 2008. [13]Schiff E,Poordad F,Jacobson I,et al.Boceprevir(B)combination therapy in null responders(NR):Response dependent on interferon responsiveness[J].J Hepatology,2008,48(2):S46. [14]Reddy R.Antiviral activity,pharmacokinetics,safety,and tolerability of R7128,a novel nucleoside HCV RNA polymerase inhibitor,following multiple,ascending oral doses inpatients with HCV genotype 1 infection who have failed prior interferon therapy[R].The 57th Annual Meeting of the American Association for the Study of Liver Diseases,2006. [15]Nicolas O.Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759[R].The 41st Annual Meeting of the European Association for the Study of the Liver,2008. [16]Nettles R.BMS-790052 is a first-in-class potent hepatitis C virus(HCV)NS5A inhibitor for patients with chronic HCV infection:Results from a proof-of-concept study[R].The 59th Annual Meeting of the American Association for the Study of Liver Diseases,2008. -
本文二维码
计量
- 文章访问数: 4623
- HTML全文浏览量: 8
- PDF下载量: 1387
- 被引次数: 0
下载:
